Back

RNA targeted therapies for lipoprotein(a) lowering: systematic review and meta analysis of siRNA and antisense oligonucleotides

29 August 2026 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Emerging lipid-lowering therapeutic modalities Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Bea Christine Joyce Buot

Dr. HB Calleja Heart and Vascular Institute, Quezon City (Philippines)

5 More presentations in this session

Presentation thumbnail
Apolipoprotein and inflammatory biomarker changes following marked triglyceride reduction with the GalNAc-conjugated APOC3 siRNA RBD5044
Ms S. Nilsson (Gothenburg, SE)
Abstract
Presentation thumbnail
Dose-related effects of olezarsen in hypertriglyceridaemia: a systematic review and meta-analysis of 2,610 patients
Miss S. Martinez-Topete (Tijuana, MX)
Abstract
Presentation thumbnail
Comparative effectiveness of probucol versus ezetimibe in statin-treated patients with established atherosclerotic cardiovascular disease
Doctor L. Liu (Tianjin, CN)
Abstract
Presentation thumbnail
Design and baseline data of AZURE-HeFH, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with heterozygous familial hypercholesterolaemia
Doctor E. Stroes (Amsterdam, NL)
Abstract
Presentation thumbnail
Evolocumab early reduces Interleukin-1β/Interleukin-17A and improves left ventricular function in ST-segment elevation myocardial infarction: an observational study in the real world
Professor J. Gao (Tianjin, CN)
Abstract

Access the full session

Session thumbnail
Emerging lipid-lowering therapeutic modalities

The Event

Event poster

ESC Congress 2026

29 August 2026 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy of inclisiran versus placebo in atherosclerotic cardiovascular disease: A systematic review and meta-analysis
19 February 2026
thumbnail
Webinar
Lipoprotein(a): a modifiable risk factor of atherosclerotic cardiovascular disease
25 October 2024
thumbnail
Congress Session
New frontiers in heart failure therapies
19 May 2025
thumbnail
Congress Presentation
Valvular proteomic and micro-CT analysis in severe aortic stenosis patients with normal and elevated lipoprotein(a) levels
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources